Beam Therapeutics Inc.

Aktienanalyse zu Beam Therapeutics Inc. (BEAM)

$24.730

+1.130 (+4.57%)Zum Schluss

Loading chart…
Hoch
24.980
Eröffnung
23.510
Volumengewichteter Durchschnittskurs
24.30
Volumen
1.78M
Marktkap.
1.97B
Tief
23.200
Umsatz
43.26M
EV/EBITDA, TTM
-0.15

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

beamtx.com

KI-Analyse of Beam Therapeutics Inc. (BEAM)

Kaufen

Beam Therapeutics Inc is a good buy right now due to its recent price increase of 4.90% over the last five days, indicating positive momentum, and a current price of $25.70, which is significantly below the analyst price target of $43. However, investors should be cautious of the negative sentiment reflected in the recent news, particularly the 6% drop in share price following the announcement related to gene editing technologies, which highlights the volatility in this sector.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Beam Therapeutics Inc. (BEAM) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -7.97.

Erwartetes KGV

Überbewertet
5J-Durchschnitt P/E
-7.97
Aktuelles P/E
0.00
Überbewertet
-2.96
Unterbewertet
-12.97

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-4.66
Aktuelles EV/EBITDA
-0.15
Überbewertet
39.51
Unterbewertet
-48.82

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
57.52
Aktuelles P/S
39.24
Überbewertet
114.84
Unterbewertet
0.20

Alphio-AI-Kursszenarien für BEAM

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%BEAM

$14.05

Szenariopreis

B

Basis

Basis · 50%BEAM

$12.36

Szenariopreis

B

Bärisch

Bärisch · 25%BEAM

$11.13

Szenariopreis

Whales, die BEAM halten

A

ARK Investment Management LLC

+ HältBEAM

+14.27%

3-Monats-Rendite

F

Farallon Capital Management, L.L.C.

+ HältBEAM

+2.77%

3-Monats-Rendite

C

Casdin Capital, LLC

+ HältBEAM

-0.48%

3-Monats-Rendite

A

Arch Venture Partners, L.P.

+ HältBEAM

-17.49%

3-Monats-Rendite

A

Alphabet Inc.

+ HältBEAM

-19.03%

3-Monats-Rendite

D

Deep Track Capital, LP

+ HältBEAM

-22.28%

3-Monats-Rendite

Event-Zeitleiste

2026-10-13 (ET)

07:30:00

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

2026-09-08 (ET)

16:30:00

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

12:30:00

Beam Therapeutics Shares Drop 12.4% to $25.99

12:30:00

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

10:30:00

Beam Therapeutics Shares Drop 12.7% to $25.88

News

BEAM FAQ – beantwortet von Alphio AI

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Beam Therapeutics Inc is a good buy right now due to its recent price increase of 4.90% over the last five days, indicating positive momentum, and a current price of $25.70, which is significantly below the analyst price target of $43. However, investors should be cautious of the negative sentiment reflected in the recent news, particularly the 6% drop in share price following the announcement related to gene editing technologies, which highlights the volatility in this sector.

Community

Mehr ↗
apemosaic30vor 3 Tagen

Successful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC

Mehr anzeigen
alpha_baker4.10.2026

$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....

Mehr anzeigen
perp_sigil4.10.2026

🚀 Top Gainers Alert: $2U2 & $BEAM Are Breaking Out! 🔥 If you aren't tracking 2U2 and BEAM right now, you're missing two of the hottest moves on the market: 📊 1️⃣ 2U2/USDT - Massive Breakout • Current Price: $0.01631 • 24h Surge: +35.80% (24h High: $0.01640) • Technical Setup: After consolidating around $0.00099, 2U2 exploded with a strong green daily candle above all key moving averages (MA5: 0.01131, MA10: 0.00964). Volume has spiked over 64.57M 2U2! 🎮 2️⃣ BEAM/USDT - GameFi Volume Spike • Current Price: $0.002562 • 24h Surge: +20.56% (24h High: $0.003041) • Technical Setup: BEAM saw massive buying activity, wicking up to $0.003041. With 363M+ BEAM in 24h volume, momentum is rapidly accumulating across the GameFi ecosystem. 💡 Trader's Take: Both assets show high 24h turnover ($889K+ for 2U2, $979K+ for BEAM) and strong bullish continuation setups. Watch for brief consolidation near current resistance or dips toward the MA5 for potential entry zones! 📈 Disclaimer: Crypto trading involves high market risk. Always manage risk & NFA.

Mehr anzeigen
picoprism4.10.2026

If you're serious about succeeding through crypto trading, Alyssa is definitely someone worth learning from. Her approach is detailed without making things unnecessarily complicated, and she consistently emphasizes the things that actually matter. Understanding the market, managing risk, and staying disciplined. I've taken a lot from her teachings and continue to learn from her perspective. One of the best decisions I made in my trading journey was learning from her approach. I'm only 4 weeks in, and I've made over $73,585 in profits. Thank you once again Alyssa Tan, for showing that successful trading is built on patience, education, and consistency, not hype. $WLD $BEAM $TRX

Mehr anzeigen
chrome_nonce4.10.2026

$STRK $QUBIC $BEAM Bitcoin is back on everyone’s radar. 🚀₿ BTC pushed back above the $85K area over the weekend after Friday’s volatility, showing that buyers are still willing to step in when the market gets shaken out. 📈 But don’t confuse momentum with certainty. The bigger story right now is the changing relationship between Bitcoin, equities, Treasury yields and expectations for the Fed. That means October could bring some serious volatility. My approach? Watch the levels, wait for confirmation, and never let FOMO become your trading strategy. 🔥🧠 The next move could be explosive — but risk management comes first.

Mehr anzeigen
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln